TDP-43 Proteinopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major TDP-43 proteinopathies markets reached a value of US$ 661.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 925.1 Million by 2034, exhibiting a growth rate (CAGR) of 3.09% during 2024-2034.
The TDP-43 proteinopathies market has been comprehensively analyzed in IMARC's new report titled "TDP-43 Proteinopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". TDP-43 proteinopathies are a group of neurodegenerative disorders characterized by the irregular accumulation of a protein called TAR DNA-binding protein 43 (TDP-43) in the brain and spinal cord. This protein is mainly essential for RNA processing and regulation, but in these diseases, it becomes abnormally modified and forms aggregates within neurons. The common symptoms associated with TDP-43 proteinopathies include changes in thinking, memory, and behavior, muscle weakness, atrophy, twitching, difficulties with movement control, language, and speech problems, apathy, disinhibition, social withdrawal, etc. Individuals suffering from these ailments may also experience trouble performing daily activities, such as dressing, eating, bathing, using tools or objects, etc. The diagnosis of TDP-43 proteinopathies typically involves a combination of clinical evaluation, medical history review, and pathological examination. Various neuroimaging techniques, like magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, may be performed to assess brain structure and function. These studies can help to identify patterns of atrophy or abnormal metabolic activity that are associated with the conditions. Furthermore, the healthcare provider may recommend an analysis of cerebrospinal fluid to measure protein levels and confirm a diagnosis.
The increasing cases of genetic mutations, which can lead to abnormal aggregation and accumulation of proteins within the body, are primarily driving the TDP-43 proteinopathies market. Besides this, the rising geriatric population, who are susceptible to age-related cellular and molecular changes, such as impaired protein homeostasis and enhanced oxidative stress, is creating a positive outlook for the market. Moreover, the widespread adoption of various medications, including antipsychotics, antidepressants, sleep aids, etc., which work by targeting specific neurotransmitter systems in the brain to alleviate disease symptoms and restore cognitive abilities in patients, is further bolstering the market growth. Apart from this, the inflating application of assistive devices, such as canes, walkers, wheelchairs, etc., since they help to reduce mobility impairments, maintain independence, and improve daily functioning, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of small molecule therapeutics that can specifically target the pathological processes associated with the condition, thereby decreasing the formation of abnormal protein aggregates, is expected to drive the TDP-43 proteinopathies market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the TDP-43 proteinopathies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for TDP-43 proteinopathies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the TDP-43 proteinopathies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the TDP-43 proteinopathies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the TDP-43 proteinopathies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current TDP-43 proteinopathies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the TDP-43 proteinopathies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the TDP-43 proteinopathies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the TDP-43 proteinopathies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies across the seven major markets?
What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies by type across the seven major markets?
How many patients are diagnosed (2018-2034) with TDP-43 proteinopathies across the seven major markets?
What is the size of the TDP-43 proteinopathies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of TDP-43 proteinopathies?
What will be the growth rate of patients across the seven major markets?
TDP-43 Proteinopathies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for TDP-43 proteinopathies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the TDP-43 proteinopathies market?
What are the key regulatory events related to the TDP-43 proteinopathies market?
What is the structure of clinical trial landscape by status related to the TDP-43 proteinopathies market?
What is the structure of clinical trial landscape by phase related to the TDP-43 proteinopathies market?
What is the structure of clinical trial landscape by route of administration related to the TDP-43 proteinopathies market?
The TDP-43 proteinopathies market has been comprehensively analyzed in IMARC's new report titled "TDP-43 Proteinopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". TDP-43 proteinopathies are a group of neurodegenerative disorders characterized by the irregular accumulation of a protein called TAR DNA-binding protein 43 (TDP-43) in the brain and spinal cord. This protein is mainly essential for RNA processing and regulation, but in these diseases, it becomes abnormally modified and forms aggregates within neurons. The common symptoms associated with TDP-43 proteinopathies include changes in thinking, memory, and behavior, muscle weakness, atrophy, twitching, difficulties with movement control, language, and speech problems, apathy, disinhibition, social withdrawal, etc. Individuals suffering from these ailments may also experience trouble performing daily activities, such as dressing, eating, bathing, using tools or objects, etc. The diagnosis of TDP-43 proteinopathies typically involves a combination of clinical evaluation, medical history review, and pathological examination. Various neuroimaging techniques, like magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, may be performed to assess brain structure and function. These studies can help to identify patterns of atrophy or abnormal metabolic activity that are associated with the conditions. Furthermore, the healthcare provider may recommend an analysis of cerebrospinal fluid to measure protein levels and confirm a diagnosis.
The increasing cases of genetic mutations, which can lead to abnormal aggregation and accumulation of proteins within the body, are primarily driving the TDP-43 proteinopathies market. Besides this, the rising geriatric population, who are susceptible to age-related cellular and molecular changes, such as impaired protein homeostasis and enhanced oxidative stress, is creating a positive outlook for the market. Moreover, the widespread adoption of various medications, including antipsychotics, antidepressants, sleep aids, etc., which work by targeting specific neurotransmitter systems in the brain to alleviate disease symptoms and restore cognitive abilities in patients, is further bolstering the market growth. Apart from this, the inflating application of assistive devices, such as canes, walkers, wheelchairs, etc., since they help to reduce mobility impairments, maintain independence, and improve daily functioning, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of small molecule therapeutics that can specifically target the pathological processes associated with the condition, thereby decreasing the formation of abnormal protein aggregates, is expected to drive the TDP-43 proteinopathies market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the TDP-43 proteinopathies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for TDP-43 proteinopathies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the TDP-43 proteinopathies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the TDP-43 proteinopathies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the TDP-43 proteinopathies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current TDP-43 proteinopathies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the TDP-43 proteinopathies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the TDP-43 proteinopathies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the TDP-43 proteinopathies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies across the seven major markets?
What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of TDP-43 proteinopathies by type across the seven major markets?
How many patients are diagnosed (2018-2034) with TDP-43 proteinopathies across the seven major markets?
What is the size of the TDP-43 proteinopathies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of TDP-43 proteinopathies?
What will be the growth rate of patients across the seven major markets?
TDP-43 Proteinopathies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for TDP-43 proteinopathies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the TDP-43 proteinopathies market?
What are the key regulatory events related to the TDP-43 proteinopathies market?
What is the structure of clinical trial landscape by status related to the TDP-43 proteinopathies market?
What is the structure of clinical trial landscape by phase related to the TDP-43 proteinopathies market?
What is the structure of clinical trial landscape by route of administration related to the TDP-43 proteinopathies market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TDP-43 PROTEINOPATHIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TDP-43 PROTEINOPATHIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TDP-43 PROTEINOPATHIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 TDP-43 PROTEINOPATHIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TDP-43 PROTEINOPATHIES - UNMET NEEDS
10 TDP-43 PROTEINOPATHIES - KEY ENDPOINTS OF TREATMENT
11 TDP-43 PROTEINOPATHIES - MARKETED PRODUCTS
11.1 List of TDP-43 Proteinopathies Marketed Drugs Across the Top 7 Markets
11.1.1 Qalsody (Tofersen) - Biogen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Exservan (Riluzole) - Aquestive Therapeutics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Radicava (Edaravone) - Mitsubishi Tanabe Pharma Corporation
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Tiglutik (Riluzole) - ITF Pharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Nuedexta (Dextromethorphan Hydrobromide And Quinidine Sulfate) - Avanir Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TDP-43 PROTEINOPATHIES - PIPELINE DRUGS
12.1 List of TDP-43 Proteinopathies Pipeline Drugs Across the Top 7 Markets
12.1.1 ABBV-CLS-7262 - Abbvie
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 FAB122 - Ferrer Internacional S.A
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Ibudilast - MediciNova
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AMDX2011P - Amydis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SAR443820 - Sanofi
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. TDP-43 PROTEINOPATHIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TDP-43 PROTEINOPATHIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TDP-43 PROTEINOPATHIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 TDP-43 Proteinopathies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 TDP-43 Proteinopathies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 TDP-43 Proteinopathies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 TDP-43 Proteinopathies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 TDP-43 Proteinopathies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 TDP-43 Proteinopathies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 TDP-43 Proteinopathies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 TDP-43 Proteinopathies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 TDP-43 Proteinopathies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 TDP-43 Proteinopathies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 TDP-43 Proteinopathies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 TDP-43 Proteinopathies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 TDP-43 Proteinopathies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 TDP-43 Proteinopathies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 TDP-43 Proteinopathies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 TDP-43 Proteinopathies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
16 TDP-43 PROTEINOPATHIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TDP-43 PROTEINOPATHIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TDP-43 PROTEINOPATHIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TDP-43 PROTEINOPATHIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TDP-43 PROTEINOPATHIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TDP-43 PROTEINOPATHIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 TDP-43 PROTEINOPATHIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TDP-43 PROTEINOPATHIES - UNMET NEEDS
10 TDP-43 PROTEINOPATHIES - KEY ENDPOINTS OF TREATMENT
11 TDP-43 PROTEINOPATHIES - MARKETED PRODUCTS
11.1 List of TDP-43 Proteinopathies Marketed Drugs Across the Top 7 Markets
11.1.1 Qalsody (Tofersen) - Biogen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Exservan (Riluzole) - Aquestive Therapeutics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Radicava (Edaravone) - Mitsubishi Tanabe Pharma Corporation
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Tiglutik (Riluzole) - ITF Pharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Nuedexta (Dextromethorphan Hydrobromide And Quinidine Sulfate) - Avanir Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TDP-43 PROTEINOPATHIES - PIPELINE DRUGS
12.1 List of TDP-43 Proteinopathies Pipeline Drugs Across the Top 7 Markets
12.1.1 ABBV-CLS-7262 - Abbvie
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 FAB122 - Ferrer Internacional S.A
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Ibudilast - MediciNova
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AMDX2011P - Amydis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SAR443820 - Sanofi
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. TDP-43 PROTEINOPATHIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TDP-43 PROTEINOPATHIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TDP-43 PROTEINOPATHIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 TDP-43 Proteinopathies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 TDP-43 Proteinopathies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 TDP-43 Proteinopathies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 TDP-43 Proteinopathies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 TDP-43 Proteinopathies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 TDP-43 Proteinopathies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 TDP-43 Proteinopathies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 TDP-43 Proteinopathies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 TDP-43 Proteinopathies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 TDP-43 Proteinopathies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 TDP-43 Proteinopathies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 TDP-43 Proteinopathies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 TDP-43 Proteinopathies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 TDP-43 Proteinopathies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 TDP-43 Proteinopathies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 TDP-43 Proteinopathies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 TDP-43 Proteinopathies - Access and Reimbursement Overview
16 TDP-43 PROTEINOPATHIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TDP-43 PROTEINOPATHIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TDP-43 PROTEINOPATHIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
